**PATENT ASSIGNMENT COVER SHEET**

Electronic Version v1.1  
Stylesheet Version v1.2

---

**SUBMISSION TYPE:** NEW ASSIGNMENT  
**NATURE OF CONVEYANCE:** ASSIGNMENT

### CONVEYING PARTY DATA

<table>
<thead>
<tr>
<th>Name</th>
<th>Execution Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>VICTOR A. LEVIN</td>
<td>10/21/2019</td>
</tr>
<tr>
<td>NOYMI YAM</td>
<td>10/21/2019</td>
</tr>
<tr>
<td>ALEXANDER VAKOULA</td>
<td>10/21/2019</td>
</tr>
</tbody>
</table>

### RECEIVING PARTY DATA

| Name: ORBUS THERAPEUTICS, INC. |  
| Street Address: 2479 EAST BAYSHORE ROAD |  
| City: PALO ALTO |  
| State/Country: CALIFORNIA |  
| Postal Code: 94303 |  

**PROPERTY NUMBERS Total: 1**

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Number:</td>
<td>16339664</td>
</tr>
</tbody>
</table>

**CORRESPONDENCE DATA**

Fax Number: (650)493-6811  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 6504615211  
Email: cricks@wsgr.com  
Correspondent Name: CHRISTINE RICKS  
Address Line 1: 650 PAGE MILL ROAD  
Address Line 4: PALO ALTO, CALIFORNIA 94304-1050

**ATTORNEY DOCKET NUMBER:** 57339-703.831  
**NAME OF SUBMITTER:** CHRISTINE RICKS  
**SIGNATURE:** /Christine Ricks/  
**DATE SIGNED:** 10/22/2019

Total Attachments: 2  
source=57339_703_831_signed_assignment#page1.tif  
source=57339_703_831_signed_assignment#page2.tif
# PATENT ASSIGNMENT

**WHEREAS,** the undersigned:

1. Victor A. Levin
   Palo Alto, CA

   (hereinafter "Inventor(s)") have invented certain new and useful improvements in FORMULATIONS FOR ADMINISTRATION OF EFLORNITINE for which application serial number 16/539,664 was submitted on April 14, 2019 to the USPTO as a National Phase Entry of an international application filed on September 29, 2017; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

**WHEREAS,** Orbus Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 2479 East Bayshore Road, Palo Alto, CA 94303, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, hereof and hereafter invented, or discovered, and in and to all applications and patents (in and to any and all patents), inventor's certificates and other rights and privileges of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

**NOW THEREFORE,** in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (e) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every Reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee’s own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfection in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; and (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissue of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

**IN WITNESS WHEREOF,** said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

<table>
<thead>
<tr>
<th>Date: 10-21-2019</th>
<th></th>
<th>Date:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Victor A. Levin</td>
<td></td>
<td>Noymi Yam</td>
<td></td>
</tr>
</tbody>
</table>

Date: Alexander Vakoula

**RECEIVED AND AGREED TO BY ASSIGNEE:**

Orbus Therapeutics, Inc.

Date: Oct. 21, 2019

Signature: [Signature]

Name: Jason Levin

Title: Chief Operating Officer
WHEREAS, the undersigned:

1. Victor A. LEVIN
   Palo Alto, CA
2. Noymi YAM
   Palo Alto, CA
3. Alexander VAKOULA
   Palo Alto, CA

(hereinafter "Inventor(s)"); have invented certain new and useful improvements in FORMULATIONS FOR ADMINISTRATION OF
EKRORNTHINE for which application serial number 16/639,644 was submitted on April 4, 2019 to the USPTO as a National Phase Entry of an
international application filed on September 29, 2017; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that
share or claim priority to or from the above application(s).

WHEREAS, Orbis Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 2429 East
Bellevue Rd., Palo Alto, CA 94303, (hereinafter "Assignee"), desires of acquiring the entire right, title and interest in and to said Application(s), and
the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by
said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection
thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the
Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from
said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said
   Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application
   that is a divisional, substitution, continuation, or continuation-in-part of any said Application(s); (d) in and to said Patent(s) and each and every patent issuing
   or remaining from any of the foregoing; (e) in and to each and every release, reexamination, removal or extension of any kind of any of the foregoing; (f) in
   and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past,
   present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future
   lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the
   right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such
   cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths,
   specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said
   Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute,
   divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissue of any said Patent(s);
   (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications
   therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings,
   priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s)
in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal
   representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered into any assignment,
   contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention,
   agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal
   representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of
   law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the
   greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute
   one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 21Oct19

[Signature]

Date: 21Oct23

[Signature]

Date: ______________

Signature: ______________

Name: Jason Levin
Title: Chief Operating Officer

RECEIVED AND AGREED TO BY ASSIGNEE:
Orbus Therapeutics, Inc.